Symptom Map of Endocrine Therapy for Breast Cancer: A Scoping Review

Conclusion Nurses caring for women receiving endocrine therapy for breast cancer should assess the 5 key symptoms identified. There remain substantial gaps in the science related to the symptom experience during endocrine therapy for breast cancer. Future studies should focus on the domains of symptom intensity and distress, specific understudied symptoms, symptom clusters, and development of symptom assessment instruments specific to symptoms associated with endocrine therapy. Implications for Practice This scoping review identified 5 well-studied and highly prevalent symptoms that should be assessed in women with breast cancer receiving endocrine therapy.
Source: Cancer Nursing - Category: Nursing Tags: ARTICLES: ONLINE ONLY Source Type: research

Related Links:

ConclusionsAmong patients ≥ 70 years old, many symptoms were significantly more frequent/severe with AIs than with SERMs, compared with those aged 56–69, which suggests a difference in the profile of adverse events according to the type of endocrine therapy and the patient’s age. It is important to consider the bene fits and risks of each treatment to optimize endocrine therapy for older patients.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
We present therapeutic options for bone metastasis using a multidisciplinary approach. Further, we describe future directions for bone metastasis management, focusing on novel bone-specific targeted therapies. PMID: 31456182 [PubMed - in process]
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
AbstractThe majority of patients with metastatic breast cancer (MBC) have hormone receptor-positive HER2-negative disease. For this subgroup, endocrine therapy is the key therapeutic option. Recently, therapeutic options have been expanded by introduction of the inhibitors of cyclin-dependent kinases 4/6 (CDK4/6i). Three compounds, palbociclib, ribociclib, and abemaciclib, have already been approved by the FDA for use together with endocrine therapy such as aromatase inhibitors (AIs) or fulvestrant; abemaciclib is also approved as a single agent. In the first-line setting, all three agents —together with an AI—...
Source: BioDrugs - Category: Drugs & Pharmacology Source Type: research
ConclusionThe HF schedule with CB in DCIS patients is well tolerated and associated with excellent clinical outcomes. This schedule affords the benefit of delivering higher dose to the lumpectomy site without protracting overall treatment time.
Source: Journal of Radiation Oncology - Category: Cancer & Oncology Source Type: research
This study was conducted to determine the prevalence and severity of menopausal symptoms and their associated risk factors among postmenopausal breast cancer patients receiving adjuvant endocrine therapy. METHODS: Postmenopausal breast cancer patients on endocrine therapy were recruited at three hospitals in Malaysia. Presence and severity of menopausal symptoms were determined using the Menopause Rating Scale. Sociodemographic and clinical data were collected from medical records. RESULTS: A total of 192 patients participated in this study. Commonly reported symptoms were musculoskeletal pain (59.9%), physical a...
Source: Climacteric - Category: Geriatrics Authors: Tags: Climacteric Source Type: research
Publication date: Available online 13 December 2018Source: Journal of Geriatric OncologyAuthor(s): Andrea Sitlinger, Rebecca A. Shelby, Alyssa N. Van Denburg, Heidi White, Sarah N. Edmond, Paul K. Marcom, Hayden B. Bosworth, Francis J. Keefe, Gretchen G. KimmickAbstractObjectiveTo explore the impact of symptoms on physical function in women on adjuvant endocrine therapy for breast cancer.MethodsEligible women were postmenopausal, had hormone receptor positive, stage I-IIIA breast cancer, completed surgery, chemotherapy, radiation, and on adjuvant endocrine therapy. At a routine follow-up visit, women (N = 107) complete...
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research
Conclusions: Fulvestrant showed encouraging clinical activity and favorable feasibility in postmenopausal women with MBC who had been treated with multiple endocrine therapies and/or cytotoxic chemotherapies. PMID: 29540055 [PubMed - as supplied by publisher]
Source: The Korean Journal of Internal Medicine - Category: Internal Medicine Authors: Tags: Korean J Intern Med Source Type: research
CONCLUSION Cognitive impairment can affect daily functioning, quality of life, and capacity to work in patients with cancer and those in remission. Consequently, cognitive assessment is now an important and necessary part of a comprehensive oncological care plan. Cancer-related cognitive impairment might be due to the direct effects of the cancer itself, nonspecific factors, or comorbid conditions that are independent of the disease and/or due to the adverse effects of the treatment or combination of treatments given for the disease. The prevalence and extent of cognitive impairment associated with cancer is recognized but...
Source: Innovations in Clinical Neuroscience - Category: Neuroscience Authors: Tags: Cognition Current Issue Neuro oncology Neurology Review cancer chemotherapy cognitive impairment neuropsychological assessment treatment Source Type: research
ConclusionsOverall, women with MBC receiving first-line endocrine therapy have a good QOL. The addition of palbociclib to letrozole maintains health-related QOL and improves pain scores in treatment-na ïve postmenopausal patients with ER+/HER2− MBC compared with letrozole alone. Significantly greater delay in deterioration of health-related QOL was observed in patients without progression versus those who progressed and in patients with an objective response versus non-responders.ClinicalTrials .gov: NCT01740427 (https://clinicaltrials.gov/ct2/show/NCT01740427)
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSION: Comorbid conditions are more likely to develop in women who have been diagnosed with hormone-dependent breast cancer than in women without cancer. Our results further support the need to develop appropriate models of care to manage the multiple chronic disorders of breast cancer survivors. PMID: 29320669 [PubMed - in process]
Source: Medical Journal of Australia - Category: General Medicine Tags: Med J Aust Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | China Health | Databases & Libraries | Endocrine Therapy | Nurses | Nursing | Pain | Science | Study | Women